ClinicalTrials.gg
Active, not recruitingNCT05043090SAMETAUpdated Oct 21, 2026

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

A Phase 3 interventional study of savolitinib and durvalumab in Papillary Renal Cell Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 139 sites in 25 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 21, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Carcinoma, Renal Cell by AstraZeneca — 2 open to participants now, 7 under way, 2 of them phase 3. Carcinoma, Renal Cell · AstraZeneca.

Enrollment
Largest of 12
148 · median 64
Started
2021
the only one that year
Phase 3
2 of 15
none open now
Registered
10th of 15
by date

Among the 15 studies in Carcinoma, Renal Cell by AstraZeneca, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 3, and was the 10th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

2 of the 15 studies in Carcinoma, Renal Cell by AstraZeneca are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Carcinoma, Renal Cell by AstraZeneca, or all of them as a file.
02

Study summary

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).

Read the detailed description

This is a Phase III, randomised, open label, 3 arm, multi-centre, international study assessing the efficacy and safety of savolitinib plus durvalumab compared with sunitinib in participants with MET-driven (without co-occurring FH mutations), unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anti-cancer therapy in the metastatic setting. The study will also investigate the contribution of durvalumab to the savolitinib plus durvalumab combination.

Approximately 200 participants will be randomised in a 2:1:1 ratio to one of the following intervention groups: savolitinib (600mg, oral, once daily) plus durvalumab (1500mg IV Q4W), sunitinib (50mg, oral, once daily for 4 consecutive weeks, followed by a sunitinib-free interval of 2-weeks, Q6W), or durvalumab monotherapy (1500mg IV Q4W).

Participants will continue to receive study intervention until objective radiological PD per RECIST 1.1 is assessed by the investigator, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.

Depending on the preferred subsequent therapy, participants randomised to the durvalumab monotherapy arm will be eligible to switch to receive savolitinib in combination with durvalumab at the time of objective radiological PD assessed by BICR per RECIST 1.1, without any intervening systemic anti-cancer therapy following discontinuation of durvalumab monotherapy.

03

Conditions studied

  • Papillary Renal Cell Carcinoma

Keywords

  • Locally
  • Advanced
  • Metastatic
  • Carcinoma
  • Savolitinib
  • Sunitinib
  • Durvalumab
  • MET Driven
  • Papillary Renal Cell Carcinoma
  • Renal Cell
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed unresectable and locally advanced or PRCC
  • PRCC must be centrally confirmed as MET-driven using a sponsor-designated central laboratory validated NGS assay
  • No prior systemic anti-cancer treatment in the metastatic setting; no prior exposure to MET inhibitors, Durvalumab or Sunitinib in any setting
  • Score >70
  • At least one lesion, not previously irradiated, that can be accurately measured at baseline
  • Adequate organ and bone marrow function
  • ≥12weeks at Day 1

Exclusion criteria

Exclusion Criteria:

  • History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs
  • Spinal cord compression or , unless asymptomatic and stable on treatment for at least 14 days prior to study intervention
  • Active or prior cardiac disease (within past 6 months) or abnormalities and/or factors/medications that may affect and/or QTc intervals
  • Active infection including , TB, and
  • Active or prior documented or inflammatory disorders
  • Receipt of within 30 days prior to the first dose of study intervention
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Arm A

    savolitinib 600mg plus durvalumab 1500mg

    Drug: savolitinib · Drug: durvalumab

  • Active comparator
    Arm B

    sunitinib 50mg

    Drug: sunitinib

  • Experimental
    Arm C

    durvalumab 1500mg

    Drug: durvalumab

Interventions

  • Tablets : 3 × 200 mg tablets once daily

    Also known as: AZD6094, HMPL-504, volitinib

  • Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks

    Also known as: MEDI4736

  • Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off

    Also known as: Sutent, SU11248

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib

    Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression.

    Time frame: Approximately 28 months post first subject randomized

Secondary outcomes

  1. Overall Survival (OS) /savolitinib plus durvalumab relative to sunitinib

    Defined as time from randomisation until the date of death due to any cause. The comparison will include all randomised participants as randomised regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy.

    Time frame: Approximately 28 months and approximately 42 months post first subject randomized

  2. Objective Response Rate (ORR) / savolitinib plus durvalumab relative to sunitinib

    Defined as the proportion of participants who have a Complete Response (CR) or Partial Response (PR) as determined by BICR per RECIST 1.1.

    Time frame: Approximately 28 months post first subject randomized

  3. Duration of Response (DoR) / savolitinib plus durvalumab relative to sunitinib

    Defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by BICR or death due to any cause.

    Time frame: Approximately 28 months post first subject randomized

  4. Disease Control Rate (DCR) at 24 and 48 weeks /savolitinib plus durvalumab relative to sunitinib

    Defined as the percentage of participants who have a CR or PR or who have Stable Disease (SD) per RECIST 1.1 as assessed by BICR for at least 23 or 47 weeks, respectively after randomisation.

    Time frame: Approximately 28 months post first subject randomized

  5. Time from randomisation to second progression or death (PFS2) /savolitinib plus durvalumab relative to sunitinib

    Defined as time from randomisation to the earliest of the progression event (following the initial progression), subsequent to the first subsequent therapy or death.

    Time frame: Approximately 28 months and 42 months post first subject randomized

  6. Assessment of patient-reported symptoms, functioning, and HRQoL /savolitinib plus durvalumab relative to sunitinib

    Time to deterioration and change from baseline in symptoms, functioning, and HRQoL as measured by FKSI-19.

    Time frame: Approximately 28 months post first subject randomized

  7. Objective Response Rate (ORR) / savolitinib plus durvalumab relative to durvalumab monotherapy

    Defined as the proportion of participants who have a Complete Response (CR) or Partial Response (PR) as determined by BICR per RECIST 1.1

    Time frame: Approximately 28 months post first subject randomized

  8. Duration of Response (DoR) / savolitinib plus durvalumab relative to durvalumab monotherapy

    Defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by BICR or death due to any cause.

    Time frame: Approximately 28 months post first subject randomized

  9. Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to durvalumab monotherapy

    Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression.

    Time frame: Approximately 28 months post first subject randomized

  10. Evaluation of the PK of savolitinib pre-dose

    Plasma concentration of savolitinib and its metabolites pre-dose (Ctrough / trough plasma concentration : measured concentration at the end of a dosing interval at steady state \[taken directly before next administration\]) in participants randomised to savolitinib plus durvalumab.

    Time frame: Approximately 28 months post first subject randomized

  11. Evaluation of the PK of savolitinib post-dose

    Plasma concentration of savolitinib and its metabolites post-dose (C1h and C3h) in participants randomised to savolitinib plus durvalumab.

    Time frame: Approximately 28 months post first subject randomized

  12. Evaluation of the PK of durvalumab pre-dose

    Serum concentration of durvalumab pre-dose (Ctrough / trough plasma concentration : measured concentration at the end of a dosing interval at steady state \[taken directly before next administration\]) in participants randomised to savolitinib plus durvalumab or durvalumab monotherapy.

    Time frame: Approximately 28 months post first subject randomized

  13. Evaluation of the PK of durvalumab / Cmax (maximum plasma concentration)

    Serum concentration of durvalumab at the end of infusion (Cmax) in participants randomised to savolitinib plus durvalumab or durvalumab monotherapy.

    Time frame: Approximately 28 months post first subject randomized

07

Study locations

139 sites
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    CABA, C1426ANZ, Argentina
  • Research Site
    Ciudad Autónoma Buenos Aires, 1125, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1120AAT, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1181ACH, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Rosario, S2002KDS, Argentina
  • Research Site
    San Miguel de Tucumán, T4000IAK, Argentina
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Macquarie University, 2109, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Belo Horizonte, 30120-320, Brazil
  • Research Site
    Brasília, 70200-730, Brazil
  • Research Site
    Cachoeiro de Itapemirim, 29308-065, Brazil
  • Research Site
    Criciúma, 88811-508, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Florianópolis, 88020-210, Brazil
  • Research Site
    Fortaleza, 60130-241, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Pelotas, 96020-080, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Rio de Janeiro, 22250-905, Brazil
  • Research Site
    Salvador, 40050-410, Brazil
  • Research Site
    São Jose Do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    São Paulo, 05652-900, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Providencia, 7510032, Chile
  • Research Site
    Santiago, 7500653, Chile
  • Research Site
    Santiago, 8420383, Chile
  • Research Site
    Temuco, 4810561, Chile
  • Research Site
    Beijing, 100039, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Prague, 100 34, Czechia
  • Research Site
    Prague, 140 59, Czechia
  • Research Site
    Prague, 15000, Czechia
  • Research Site
    Prague, 180 81, Czechia
  • Research Site
    Bordeaux, 33075, France
  • Research Site
    Quimper, 29107, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Shatin, 00000, Hong Kong
  • Research Site
    Bangalore, 560027, India
  • Research Site
    Belagavi, 590010, India
  • Research Site
    Jaipur, 302002, India
  • Research Site
    Mysore, 570001, India
  • Research Site
    Nashik, 422004, India
  • Research Site
    Haifa, 91096, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Arezzo, 52100, Italy
  • Research Site
    Avellino, 83100, Italy
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Reggio Emilia, 42123, Italy
  • Research Site
    Tricase, 73039, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    Querétaro, 76090, Mexico
  • Research Site
    Toluca, 50090, Mexico
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Arnhem, 6815 AD, Netherlands
  • Research Site
    Rotterdam, 3045 PM, Netherlands
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Gdynia, 81-519, Poland
  • Research Site
    Krakow, 30-348, Poland
  • Research Site
    Otwock, 05-400, Poland
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Cluj-Napoca, 400015, Romania
  • Research Site
    Cluj-Napoca, 400641, Romania
  • Research Site
    Craiova, 200094, Romania

Showing the first 100 of 139 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Jackson-Spence F, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite FC, Ralph C, Srinivasan G, Mendez-Vidal MJ, Childress M, Li W, Boyle P, Gasco A, Markovets A, Hartmaier R, Ackerman C, Szabados BE, Priyadarshini G, Jamal F, Powles T, Suarez C. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. J Clin Oncol. 2026 Apr 20;44(12):1076-1082. doi: 10.1200/JCO-25-01840. Epub 2026 Mar 20. PubMed 41861260 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Dec 2025, 50 months.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 50 months is close to that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2021
First posted
Sep 13, 2021
StartActual
Oct 28, 2021
Primary completionActual
Dec 31, 2025
CompletionEst.
Feb 1, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 Argentina, 1 Australia)
  • Research Site · Córdoba, Argentina
  • Research Site · St Leonards, Australia
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    2 sites added
    Show 2 added (1 Argentina, 1 Australia)
    • Research Site · Córdoba, Argentina
    • Research Site · St Leonards, Australia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05043090
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Oct 28, 2021
Primary completion
Dec 31, 2025
Completion
Feb 1, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Toni Choueiri
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Savolitinib · Durvalumab

Start the discussion